Tandem Diabetes Care, Inc. (NASDAQ: TNDM) was last seen trading at $22.60, and its 52-week range of $9.98 to $38.28 only shows part of the problem for a rough year. This was briefly a $150 stock at the end of 2021. Now Canaccord Genuity is predicting a 50%-plus recovery for Tandem Diabetes, raising its price target to $35 from $24 and reiterating its Buy rating.
Canaccord is bullish on med-tech for 2026 as small/mid-cap valuations are depressed. The firm expects M&S to increase in 2026 and also sees how A.I. is now more able to improve treatments and outcomes. While Tandem is -36% YTD, it has recovered 100% from its lows in August and it still has only a $1.5 billion market cap.
Amicus Therapeutics Inc. (NASDAQ: FOLD) may have 50% implied upside in 2026 if Citigroup is right is in its thesis. Citi started Amicus with a Buy rating and a $17 price target, versus a $10.89 prior closing price. Amicus is looking to commercialize rare disease therapies, and Citi sees its Galafold and PomOp positioned to have combined sales o0f more than $1 billion in 2028.
Amicus had 2024 total revenues of $528 million, and the consensus estimates are projecting $629 million in 2025 and $744 million in 2026. It hit a 52-week high of $11.14 on this positive research call (with a $5.51 low over the last year) and it has a $3.4 billion market cap.
